Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that Wild type ALK, Wild type EGFR status confers therapeutic sensitivity to Carboplatin, Ipilimumab, Nivolumab, Paclitaxel in patients with Non-Small Cell Lung Cancer.
The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with ipililumab, carboplatin, and paclitaxel for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic squamous non-small cell lung cancer (NSCLC) whose tumors have no sensitising EGFR mutation or ALK translocation.
This statement is based on a regulatory approval from the Health Service Executive:
First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.